Abivax SA Sponsored ADR (EURONEXT:ABVX) priced an upsized 7.36M ADS U.S. offering at $125 (~$920M gross) as it advances obefazimod 50 mg—with promising Week 44 UC remission/response and endoscopic gains but some malignancy events—eyeing a U.S. NDA in Q4 2026.
Previous Week Recap
- Abivax Upsized ADS Offering: Abivax (ABVX) priced an upsized U.S. ADS offering: 7.36M ADSs at $125, gross ~$920M (net ≈ $874.1M). Offering expected to close July 6, 2026. ADSs trade on Nasdaq under ABVX.
- Obefazimod UC Trial: Remission, NDA Planned: Abivax ABVX: Week 44 maintenance for obefazimod 50 mg in UC—remission 37.2%, response 61.5%, endoscopic improvement 48%, some malignancy events reported; U.S. NDA planned Q4 2026.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.